Umut Sarpel1, Maria Suprun2, Anastasia Sofianou3, Yaniv Berger1, Andreas Tedjasukmana4, Zennur Sekendiz5, Emilia Bagiella2, Myron E Schwartz6. 1. Division of Surgical Oncology, Department of Surgery, New York, NY, USA. 2. Department of Population, Health Science and Policy, New York, NY, USA. 3. Department of Strategic Planning, New York, NY, USA. 4. Department of Neurosurgery, New York, NY, USA. 5. Ross University, Roseau, Dominica. 6. The Recanati/Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Abstract
INTRODUCTION: Liver transplantation is the most effective treatment for hepatocellular carcinoma (HCC) in eligible patients, but is not accessed equally by all. We explored the effects of race and socioeconomic factors on transplantation for HCC while controlling for stage, resection status, and transplant candidacy. PATIENTS AND METHODS: All HCC patients, 2003-2013, were retrospectively analyzed using multivariate analysis to explore differences in transplantation rates among cohorts. RESULTS: Of 3078 HCC patients, 754 (24%) were considered transplant eligible. Odds of transplantation were significantly higher for those with commercial insurance (OR = 1.99, 95% CI [1.42, 2.79]) and lower for black patients (OR = 0.55, 95% CI [0.33, 0.91]). Asians were more likely to be resected than white patients with similarly staged tumors and transplant criteria (p < 0.001). Patients not listed for transplantation for non-medical reasons were more likely to be government-insured (p = 0.02) and not white (p = 0.05). No step along the transplantation pathway was identified as the dominant hurdle. DISCUSSION: Patients who are black or government-insured are significantly less likely to undergo transplantation for HCC despite controlling for tumor stage, resection status, and transplant eligibility. Asian patients have higher rates of hepatic resection, but also appear to have lower transplantation rates beyond this effect.
INTRODUCTION: Liver transplantation is the most effective treatment for hepatocellular carcinoma (HCC) in eligible patients, but is not accessed equally by all. We explored the effects of race and socioeconomic factors on transplantation for HCC while controlling for stage, resection status, and transplant candidacy. PATIENTS AND METHODS: All HCCpatients, 2003-2013, were retrospectively analyzed using multivariate analysis to explore differences in transplantation rates among cohorts. RESULTS: Of 3078 HCCpatients, 754 (24%) were considered transplant eligible. Odds of transplantation were significantly higher for those with commercial insurance (OR = 1.99, 95% CI [1.42, 2.79]) and lower for black patients (OR = 0.55, 95% CI [0.33, 0.91]). Asians were more likely to be resected than white patients with similarly staged tumors and transplant criteria (p < 0.001). Patients not listed for transplantation for non-medical reasons were more likely to be government-insured (p = 0.02) and not white (p = 0.05). No step along the transplantation pathway was identified as the dominant hurdle. DISCUSSION: Patients who are black or government-insured are significantly less likely to undergo transplantation for HCC despite controlling for tumor stage, resection status, and transplant eligibility. Asian patients have higher rates of hepatic resection, but also appear to have lower transplantation rates beyond this effect.
Authors: Victor Zaydfudim; Martin A Whiteside; Marie R Griffin; Irene D Feurer; J Kelly Wright; C Wright Pinson Journal: Ann Surg Oncol Date: 2010-06-29 Impact factor: 5.344
Authors: Linda L Wong; Brenda Hernandez; Sandi Kwee; Cheryl L Albright; Gordon Okimoto; Naoky Tsai Journal: Am J Surg Date: 2012-01-09 Impact factor: 2.565
Authors: Sandy L Kwong; Susan L Stewart; Christopher A Aoki; Moon S Chen Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-09-07 Impact factor: 4.254
Authors: Pratima Sharma; Vijayan Balan; Jose L Hernandez; Ann M Harper; Erick B Edwards; Hector Rodriguez-Luna; Thomas Byrne; Hugo E Vargas; David Mulligan; Jorge Rakela; Russell H Wiesner Journal: Liver Transpl Date: 2004-01 Impact factor: 5.799
Authors: Avo Artinyan; Brian Mailey; Nicelio Sanchez-Luege; Joshua Khalili; Can-Lan Sun; Smita Bhatia; Lawrence D Wagman; Nicholas Nissen; Steven D Colquhoun; Joseph Kim Journal: Cancer Date: 2010-03-01 Impact factor: 6.860
Authors: Shoshana Adler Jaffe; Orrin Myers; Angela L W Meisner; Charles L Wiggins; Deirdre A Hill; Jean A McDougall Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-12-03 Impact factor: 4.254
Authors: Michael R Poulson; B Aldana Blanco; Alaina D Geary; Kelly M Kenzik; David B McAneny; Jennifer F Tseng; Teviah E Sachs Journal: HPB (Oxford) Date: 2021-01-19 Impact factor: 3.842
Authors: Meryl D Colton; DeLayna Goulding; Alina Beltrami; Carrye Cost; Anna Franklin; Myles G Cockburn; Adam L Green Journal: Cancer Med Date: 2019-06-26 Impact factor: 4.452
Authors: Cortlandt M Sellers; Johannes Uhlig; Johannes M Ludwig; Tamar Taddei; Stacey M Stein; Joseph K Lim; Hyun S Kim Journal: Cancer Med Date: 2019-08-22 Impact factor: 4.452
Authors: Tali Shaltiel; Serena Zheng; Cleo Siderides; Elizabeth M Gleeson; Jacquelyn Carr; Eric R Pletcher; Noah A Cohen; Benjamin J Golas; Deepa R Magge; Daniel M Labow; Andrea D Branch; Umut Sarpel Journal: Cancer Date: 2021-02-25 Impact factor: 6.921